Risperidone in treatment-refractory schizophrenia

Donna A. Wirshing, Barringer D. Marshall, Michael F. Green, Jim Mintz, Stephen R. Marder, William C. Wirshing

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Objective: The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia. Method: Sixty-seven medication- unresponsive subjects were randomly assigned to treatment with risperidone (N=34) or haloperidol (N=33). After a 3-7 day-placebo washout period, there was a 4-week, double-blind, fixed-dose comparison trial that was followed by a 4-week, flexible-dose phase. Measures of clinical change were quantified by standard psychopathologic and neuromotor instruments. Results: Risperidone demonstrated clinical efficacy superior to that of haloperidol on the total Brief Psychiatric Rating Scale (BPRS) after the first 4 weeks of treatment. Risperidone did not show any advantage over haloperidol after an additional 4 weeks. Overall improvement on the BPRS at 4 weeks was significantly better for the risperidone group (24%) than for the haloperidol group (11%). Risperidone-treated subjects were significantly less likely than haloperidol- treated subjects to require concomitant anticholinergic medication after 4 weeks (20% versus 63%); they also had significantly less observable akathisia (24% versus 53%) and significantly less severe tardive dyskinesia. Baseline characteristics that correlated significantly with risperidone response were positive symptoms, conceptual disorganization, akathisia, and tardive dyskinesia. Conclusions: Risperidone was better tolerated and more effective in a subset of patients with treatment-refractory schizophrenia. Positive psychotic symptoms and extrapyramidal side effects at baseline appear to be powerful predictors of subsequent response to risperidone.

Original languageEnglish (US)
Pages (from-to)1374-1379
Number of pages6
JournalAmerican Journal of Psychiatry
Volume156
Issue number9
StatePublished - Sep 1999
Externally publishedYes

Fingerprint

Risperidone
Schizophrenia
Haloperidol
Brief Psychiatric Rating Scale
Psychomotor Agitation
Therapeutics
Cholinergic Antagonists
Placebos
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Wirshing, D. A., Marshall, B. D., Green, M. F., Mintz, J., Marder, S. R., & Wirshing, W. C. (1999). Risperidone in treatment-refractory schizophrenia. American Journal of Psychiatry, 156(9), 1374-1379.

Risperidone in treatment-refractory schizophrenia. / Wirshing, Donna A.; Marshall, Barringer D.; Green, Michael F.; Mintz, Jim; Marder, Stephen R.; Wirshing, William C.

In: American Journal of Psychiatry, Vol. 156, No. 9, 09.1999, p. 1374-1379.

Research output: Contribution to journalArticle

Wirshing, DA, Marshall, BD, Green, MF, Mintz, J, Marder, SR & Wirshing, WC 1999, 'Risperidone in treatment-refractory schizophrenia', American Journal of Psychiatry, vol. 156, no. 9, pp. 1374-1379.
Wirshing DA, Marshall BD, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. American Journal of Psychiatry. 1999 Sep;156(9):1374-1379.
Wirshing, Donna A. ; Marshall, Barringer D. ; Green, Michael F. ; Mintz, Jim ; Marder, Stephen R. ; Wirshing, William C. / Risperidone in treatment-refractory schizophrenia. In: American Journal of Psychiatry. 1999 ; Vol. 156, No. 9. pp. 1374-1379.
@article{467c08ac259e4c1bb63c5e3a8779a645,
title = "Risperidone in treatment-refractory schizophrenia",
abstract = "Objective: The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia. Method: Sixty-seven medication- unresponsive subjects were randomly assigned to treatment with risperidone (N=34) or haloperidol (N=33). After a 3-7 day-placebo washout period, there was a 4-week, double-blind, fixed-dose comparison trial that was followed by a 4-week, flexible-dose phase. Measures of clinical change were quantified by standard psychopathologic and neuromotor instruments. Results: Risperidone demonstrated clinical efficacy superior to that of haloperidol on the total Brief Psychiatric Rating Scale (BPRS) after the first 4 weeks of treatment. Risperidone did not show any advantage over haloperidol after an additional 4 weeks. Overall improvement on the BPRS at 4 weeks was significantly better for the risperidone group (24{\%}) than for the haloperidol group (11{\%}). Risperidone-treated subjects were significantly less likely than haloperidol- treated subjects to require concomitant anticholinergic medication after 4 weeks (20{\%} versus 63{\%}); they also had significantly less observable akathisia (24{\%} versus 53{\%}) and significantly less severe tardive dyskinesia. Baseline characteristics that correlated significantly with risperidone response were positive symptoms, conceptual disorganization, akathisia, and tardive dyskinesia. Conclusions: Risperidone was better tolerated and more effective in a subset of patients with treatment-refractory schizophrenia. Positive psychotic symptoms and extrapyramidal side effects at baseline appear to be powerful predictors of subsequent response to risperidone.",
author = "Wirshing, {Donna A.} and Marshall, {Barringer D.} and Green, {Michael F.} and Jim Mintz and Marder, {Stephen R.} and Wirshing, {William C.}",
year = "1999",
month = "9",
language = "English (US)",
volume = "156",
pages = "1374--1379",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "9",

}

TY - JOUR

T1 - Risperidone in treatment-refractory schizophrenia

AU - Wirshing, Donna A.

AU - Marshall, Barringer D.

AU - Green, Michael F.

AU - Mintz, Jim

AU - Marder, Stephen R.

AU - Wirshing, William C.

PY - 1999/9

Y1 - 1999/9

N2 - Objective: The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia. Method: Sixty-seven medication- unresponsive subjects were randomly assigned to treatment with risperidone (N=34) or haloperidol (N=33). After a 3-7 day-placebo washout period, there was a 4-week, double-blind, fixed-dose comparison trial that was followed by a 4-week, flexible-dose phase. Measures of clinical change were quantified by standard psychopathologic and neuromotor instruments. Results: Risperidone demonstrated clinical efficacy superior to that of haloperidol on the total Brief Psychiatric Rating Scale (BPRS) after the first 4 weeks of treatment. Risperidone did not show any advantage over haloperidol after an additional 4 weeks. Overall improvement on the BPRS at 4 weeks was significantly better for the risperidone group (24%) than for the haloperidol group (11%). Risperidone-treated subjects were significantly less likely than haloperidol- treated subjects to require concomitant anticholinergic medication after 4 weeks (20% versus 63%); they also had significantly less observable akathisia (24% versus 53%) and significantly less severe tardive dyskinesia. Baseline characteristics that correlated significantly with risperidone response were positive symptoms, conceptual disorganization, akathisia, and tardive dyskinesia. Conclusions: Risperidone was better tolerated and more effective in a subset of patients with treatment-refractory schizophrenia. Positive psychotic symptoms and extrapyramidal side effects at baseline appear to be powerful predictors of subsequent response to risperidone.

AB - Objective: The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia. Method: Sixty-seven medication- unresponsive subjects were randomly assigned to treatment with risperidone (N=34) or haloperidol (N=33). After a 3-7 day-placebo washout period, there was a 4-week, double-blind, fixed-dose comparison trial that was followed by a 4-week, flexible-dose phase. Measures of clinical change were quantified by standard psychopathologic and neuromotor instruments. Results: Risperidone demonstrated clinical efficacy superior to that of haloperidol on the total Brief Psychiatric Rating Scale (BPRS) after the first 4 weeks of treatment. Risperidone did not show any advantage over haloperidol after an additional 4 weeks. Overall improvement on the BPRS at 4 weeks was significantly better for the risperidone group (24%) than for the haloperidol group (11%). Risperidone-treated subjects were significantly less likely than haloperidol- treated subjects to require concomitant anticholinergic medication after 4 weeks (20% versus 63%); they also had significantly less observable akathisia (24% versus 53%) and significantly less severe tardive dyskinesia. Baseline characteristics that correlated significantly with risperidone response were positive symptoms, conceptual disorganization, akathisia, and tardive dyskinesia. Conclusions: Risperidone was better tolerated and more effective in a subset of patients with treatment-refractory schizophrenia. Positive psychotic symptoms and extrapyramidal side effects at baseline appear to be powerful predictors of subsequent response to risperidone.

UR - http://www.scopus.com/inward/record.url?scp=0032884391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032884391&partnerID=8YFLogxK

M3 - Article

C2 - 10484947

AN - SCOPUS:0032884391

VL - 156

SP - 1374

EP - 1379

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 9

ER -